Oligomycin- Introduction and Mechanism of Action

Thursday, July 20, 2017

Oligomycin is a group of Streptomyces macrolides that bind to the Oligomycin sensitivity-conferring protein (OSCP) at the F(o) subunits 6 and 9 which are found in the stalk of the F1F0-ATPase complex. This binding blocks proton conductance across the synthase complex and inhibits the synthesis of mitochondrial ATP. As an additional result, the proton pumps of the electron transport chain are unable to operate because the gradient becomes too strong for them to overcome. NADH is then no longer oxidized and the citric acid cycle ceases to operate because the NAD+ concentrationfalls below the concentration that these enzymes can use.1,2

The Oligomycin complex was first reported in 1954, isolated from a strain of Streptomyces diastatochromogenes.3 Oligomycin have been attributed antifungal,4 antitumor,5,6 immunosuppresive,7 and insecticidal and nematocidal8 properties. There are several known Oligomycins, named Oligomycin A-G. Different Oligomycin isomers are highly specific for the disruption of mitochondrial metabolism. Oligomycin A, a dominant analog of the isomers, is an inhibitor of mitochondrial F1F0 ATP synthase that induces apoptosis in a variety of cell types (average GI50 = 270 nM).9-11 Oligomycin A specifically exhibits antifungal, antitumor, and nematocidal activities, but has poor solubility in water and other biocompatible solvents, which limits its clinical application.12

 Oligomycin A

 

Occurrence and Toxicity

In 2001, Oligomycin A was labeled among the top 0.1% most cell line selective cytotoxic agent from 37,000 molecules tested against the National Cancer Institute (NCI) panel of 60 human cancer cell lines, with ∼35% of cell lines exquisitely sensitive (GI50 10 nM) and the remaining less sensitive (GI50 1-10 μM).13 In 2004 an Oligomycin was described as an inhibitor of the multidrug resistance efflux pump P-glycoprotein (P-gp).14 In 2016, Salim et al. studied an Oligomycin class of Streptomyces polyketides as inhibitors of oncogenic mutant K-Ras plasma membrane localization, thus are putative cancer chemotherapeutics.15
The Oligomycins are stable compounds. Their inhibitory potency is little changed on storage at pH 3 to 10 at 37°C for 54 h. As mentioned, they are almost insoluble in water but are soluble in water-miscible solvents such as ethanol, methanol, dimethyl sulfoxide, dimethylformamide acetone, glacial acetic acid and ether. Oligomycins are usually dissolved in ethanol and stored in a refrigerator. Their maximum solubility in ethanol seems to be not more than 10 mM (about 8 mg/ml).16

 

Biological Activit

Oligomycin A has been studied for the ability to induce different types of cell death.17 Tettamanti at al. induced oncosis in the IPLB-LdFB insect cell line by using Oligomycin A, by observation of a time-dependent reduction in ATP concentration from 2 h to 24 h. The oncotic pattern occurs after a 22 h incubation with Oligomycin A and is followed by a necrotic phenotype.

Since Oligomycin blocks oxidative phosphorylation, it makes cells more dependent on glycolysis and more sensitive to inhibitors of glycolysis such as 2-deoxy-D-glucose.18 Cells that are deficient in HIF-1 α, which induces increased glucose uptake and glycolysis, are more sensitive to the toxicity of Oligomycin whereas cells that are sufficient in HIF-1α are less sensitive to Oligomycin under hypoxic conditions (where HIF-1α accumulates). However, because Oligomycin blocks reduction of O2 by the electron transport, it maintains higher levels of O2 and modulates down the protective effect of HIF-1α under normoxic conditions.19-21 As a consequence of Oligomycin effects, higher eukaryotic cells may develop serious syndromes, including neurological disorders, that may degenerate into life-threatening diseases. Thus, Oligomycins are not suitable for therapeutic applications.

 To summarize, the Oligomycin group may serve as an antibiotic, yet the mechanism of action may affect healthy cells as well, and it is not used therapeutically.  Oligomycin A is used to modulate ATP synthesis in studies of cell or organ function. Administering Oligomycin to an individual may result in high elevation of lactate level accumulating in the blood and urine.

 

References: 
  1. Oligomycin frames a common drug-binding site in the ATP synthase., J. Symersky, D. Osowski, D. E. Walters and M. Mueller David, Proc. Natl. Acad. Sci. U.S.A., 2012, 109, 13961–13965. 
  2. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells., Y. C. Li, K. P. Fung, T. T. Kwok, C. Y. Lee, Y. K. Suen and S. K. Kong, Chemotherapy, 2004, 50, 55–62. 
  3. Oligomycin, a new antifungal antibiotic., R. M. Smith, W. H. Peterson and E. McCoy, Antibiot. Chemother., 1954, 4, 962–970. • Separation and Preliminary Characterization of Oligomycins A, B and C. S. Masamune, J. M. Sehgal, E. E. Van Tamelen, F. M. Strong and W. H. Peterson, J. Am. Chem. Soc., 1958, 80, 6092–6095.
  4. Oligomycin E, a new antitumor antibiotic produced by Streptomyces sp. MCI-2225. K. Kobayashi, C. Nishino, J. Ohya, S. Sato, T. Mikawa, Y. Shiobara, M. Kodama and N. Nishimoto, J. Antibiot., 1987, 40, 1053–1057. 
  5. 44-homooligomycins A and B, new antitumor antibiotics from Streptomyces bottropensis producing organism, fermentation, isolation, structure elucidation and biological properties. M. Yamazaki, T. Yamashita, T. Harada, T. Nishikiori, S. Saito, N. Shimada and A. Fujii, J. Antibiot., 1992, 45, 171–179. 
  6. Oligomycin F, a new immunosuppressive homologue of oligomycin A. H. Laatsch, M. Kellner, G. Wolf, Y. S. Lee, F. Hansske, S. Konetschny-Rapp, U. Pessara, W. Scheuer and H. Stockinger, J. Antibiot., 1993, 46, 1334–1341. 
  7. Isolation of a New Antibiotic Oligomycin G Produced by Streptomyces sp. WK-6150. Y. Enomoto, K. Shiomi, A. Matsumoto, Y. Takahashi, Y. Iwai, A. Harder, H. Kolbl, H. B. Woodruff and S. Omura, J. Antibiot., 2001, 54, 308–313. 
  8. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. A.R. Salomon, D.W. Voehringer, L.A. Herzenberg, et al. Chemistry & Biology, 2001, 8, 71-80.
  9. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Y.K. Shin, B.C. Yoo, H.J. Chang, et al.  Cancer Research, 2005, 65, 8, 3162-3170.
  10. Oligomycin F, a new immunosuppressive homologue of oligomycin A. H. Laatsch, , M. Kellner, G. Wolf, et al.  J. Antibiotics, 1993, 46, 9, 1334-1341.
  11. Process optimization of the preparation of oligomycin-loaded folate-conjugated chitosan nanoparticles as a tumor-targeted drug delivery system using a two-level factorial design method. Y. Zu, Q. Zhao, X. Zhao, et al.  Int. J. Nanomedicine 2011, 6, 3429-3441.
  12. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. A. R. Salomon, D. W. Voehringer, L. A. Herzenberg and C. Khosla, Chem. Biol., 2001, 8, 71–80.
  13. Oligomycins as inhibitors of K-Ras plasma membrane localization. A. A. Salim, L. Tan, X. C. Huang, K.-J. Cho, E. Lacey, J. F. Hancock and R. J. Capon. Org. Biomol. Chem., 2016, 14, 711-715.
  14. The effect of oligomycin, gramicidin and other antibiotics on reversal of mitochondrial swelling by adenosine trisphosphate. D. Neubert, A. Lehninger. Biochimica et Biophysica Acta. 1962, 62, 3, 556-565.
  15. Oligomycin A induces autophagy in the IPLB-LdFB insect cell line. G. Tettamanti, D. Malagoli, E. Marchesini, et al. Cell Tissue Res., 2006, 326, 179-186.
  16. Oligomycin A and the IPLB-LdFB insect cell line: Actinand mitochondrial responses. G. Tettamantia, D. Malagolib, E. Ottavianib, M. de Eguileor, Cell Biol. Int. 2007, 32, 2, 287-292.
  17. Activation of HIF-1a in Exponentially Growing Cells Via Hypoxic Stimulation Is Independent of the Akt/mTOR Pathway. F. Dayan, R. L. Bilton, J. Laferriere, E. Trottier, D. Roux, J. Pouyssegur, and N. M. Mazure, J. Cell. Physiol. 218, 167-174.
  18. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. J. C. Maher, M. Wangpaichitr, N. Savaraj, M. Kurtoglu, and T. J. Lampidis, Mol. Cancer Ther., 2007, 6, 732–41.
  19. Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F0F1-ATPase. A. R. Salomon, D. W. Voehringer, L. A. Herzenberg, and C. Khosla, PNAS, 2000, 97, 14766–14771.
  20. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells. Y. Gong, F. H. Agani,, Am. J. Physiol. Cell Physiol. 2005, 288, 5, C1023-C1029.